Cargando…

Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial

BACKGROUND: Residual breast cancer after neo-adjuvant chemotherapy (NACT) predicts disease outcome and is a surrogate for survival in aggressive breast cancer (BC) subtypes. Pathological complete response (pCR) rate, however, is lower for luminal B BC in comparison to the triple negative (TNBC) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Caluwé, Alex, Buisseret, Laurence, Poortmans, Philip, Van Gestel, Dirk, Salgado, Roberto, Sotiriou, Christos, Larsimont, Denis, Paesmans, Marianne, Craciun, Ligia, Stylianos, Drisis, Vandekerckhove, Christophe, Reyal, Fabien, Isabelle, Veys, Eiger, Daniel, Piccart, Martine, Romano, Emanuela, Ignatiadis, Michail
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343924/ https://www.ncbi.nlm.nih.gov/pubmed/34362344 http://dx.doi.org/10.1186/s12885-021-08601-1

Ejemplares similares

Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

Correction: Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis
por: Azim, Hatem A., et al.
Publicado: (2013)

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2021)

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer
por: Gombos, Andrea, et al.
Publicado: (2022)

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer
por: Buisseret, Laurence, et al.
Publicado: (2016)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

The current use and attitudes towards tumor genome sequencing in breast cancer
por: Gingras, I., et al.
Publicado: (2016)

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2016)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
por: Buisseret, Laurence, et al.
Publicado: (2023)

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
por: de Azambuja, E, et al.
Publicado: (2007)

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
por: Raspé, Eric, et al.
Publicado: (2017)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer
por: Amato, Ottavia, et al.
Publicado: (2023)

Low CD10 mRNA Expression Identifies High-Risk Ductal Carcinoma In Situ (DCIS)
por: Toussaint, Jérôme, et al.
Publicado: (2010)

HER2-Positive Circulating Tumor Cells in Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Significance of neo-angiogenesis and immuno-surveillance cells in squamous cell carcinoma of the tongue
por: Alkhabuli, Juma O.
Publicado: (2007)

Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
por: Randrian, Violaine, et al.
Publicado: (2021)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology
por: Fumagalli, Debora, et al.
Publicado: (2014)

Palbociclib with letrozole as second-line neo-systemic therapy after failure of neo-adjuvant chemotherapy for luminal type breast cancer: A case report
por: Jung, Sung Ui, et al.
Publicado: (2021)

Survivin Expression in Luminal Breast Cancer and Adjacent Normal Tissue for Immuno-Oncology Applications
por: Wright, Sharon, et al.
Publicado: (2023)

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
por: Loi, Sherene, et al.
Publicado: (2009)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients
por: Rothé, Françoise, et al.
Publicado: (2021)

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
por: Bareche, Yacine, et al.
Publicado: (2019)

Neoadjuvant treatment: the future of patients with breast cancer
por: Reyal, F, et al.
Publicado: (2018)

Luminal Progenitors Restrict Their Lineage Potential during Mammary Gland Development
por: Rodilla, Veronica, et al.
Publicado: (2015)

NeoCheck: A New Checklist to Assess Performance during Newborn Life Support—A Validation Study
por: Bibl, Katharina, et al.
Publicado: (2023)

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial
por: Di Cosimo, Serena, et al.
Publicado: (2020)

NEO E-vita—NEO era!
por: Jakob, Heinz, et al.
Publicado: (2022)

Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients
por: Bohlok, Ali, et al.
Publicado: (2020)

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
por: Cascone, Tina, et al.
Publicado: (2023)

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
por: Rothé, Françoise, et al.
Publicado: (2011)

Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
por: Toussaint, Jérôme, et al.
Publicado: (2009)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer
por: Solinas, Cinzia, et al.
Publicado: (2017)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registry
por: Philippson, Catherine, et al.
Publicado: (2022)

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
por: Wirapati, Pratyaksha, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_jimj3fe2emdt8errdo6353ajf0